News
31 March 2020

EIB finances AM-Pharma's development of acute kidney injury treatment

In:
Infrastructure
Region:
Europe

The EIB and Utrecht-based AM-Pharma have signed a €24 million financing agreement. The funds will be used to accelerate the development of the clinical stage biopharmaceutical company’s recombinant alkaline phosphatase enzyme, which is used to treat acute kidney injury (AKI). The...

Exclusive subscriber content…

If you are a TXF subscriber, please login to continue reading

Login

Not yet a subscriber? Join us today to continue accessing content without any restrictions

View our subscription options

Or to request access to TXF Intelligence contact us

Request Access

You might also like


Perspective
31 October 2025

Aliança Energia: Vale taps GIP’s firepower

Global Infrastructure Partners' $1 billion swoop for Aliança Energia highlights the changing structure of Brazil's electricity market. Big commodities producers and...

Interview
07 November 2025

Pertamina’s Bagus talks strategic finance

Andy Bagus, senior vice-president treasury and strategic finance, at Indonesia’s national oil company Pertamina discusses project and export finance strategy amid a volatile...